Designing a Novel Immunotoxin against Prostate Cancer based on PE40 Toxin: An In silico Approach

Area of Science:

• Oncology
• Biotechnology
• Computational Biology

Background:

• Prostate cancer is a leading cause of cancer death globally.
• Traditional treatments have limitations in efficacy and side effects.
• Targeted cancer therapies, like immunotoxins, offer a promising alternative.

Purpose of the Study:

• To design and computationally assess a novel immunotoxin for prostate cancer therapy.
• To evaluate the structural integrity, physicochemical properties, and allergenicity of the designed immunotoxin.
• To predict the binding affinity and stability of the immunotoxin with its target.

Main Methods:

• A prostate-specific single-chain variable fragment (scFv) was fused with a truncated Pseudomonas exotoxin.
• In silico tools (SOPMA, Protparam, AllergenFP, ITASSER, ProSa-web, PROCHECK, Cluspro, GROMACS) were used for structure prediction, validation, docking, and molecular dynamics simulation.
• Analysis of Root Mean Square Fluctuation (RMSF) was performed to assess complex stability.

Main Results:

• The designed immunotoxin exhibited structural stability with low RMSF values (0.292 Å) compared to the PSMA receptor (0.478 Å).
• Computational predictions indicated the immunotoxin is non-allergenic.
• The model suggests effective binding of the immunotoxin to PSMA.

Conclusions:

• The designed immunotoxin demonstrates favorable structural stability and non-allergenic characteristics.
• The immunotoxin shows potential for binding to Prostate-Specific Membrane Antigen (PSMA).
• This computationally validated immunotoxin warrants further experimental investigation for prostate cancer treatment.